GlassScriptPhysician profile
Jonathan M Rodrigues
NPI 1326351131
$54,189.87
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $2,364 · 2021: $262 · 2022: $202.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47,090.18 | 2019-2022 | |
| Csl Behring | $6,343.34 | 2019-2022 | |
| Glaxosmithkline, LLC. | $214.36 | 2019-2022 | |
| Genzyme Corporation | $188.58 | 2019-2022 | |
| Horizon Therapeutics Plc | $44.67 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.50 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $41.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $34.04 | 2022 | |
| Octapharma USA, INC. | $31.03 | 2019-2020 | |
| Pfizer INC. | $28.43 | 2019-2021 | |
| Grifols USA, LLC | $27.91 | 2019 | |
| Incyte Corporation | $19.92 | 2022 | |
| Phadia US INC. | $16.51 | 2021 | |
| Uswm, LLC | $15.00 | 2021 | |
| Pharming Healthcare, INC. | $13.58 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $13.39 | 2019 | |
| Genentech USA, INC. | $11.94 | 2021 | |
| Shire North American Group INC | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rodrigues listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.